Dude, you are 3 months late to the party. This thread has transformed to a Marsman's Journey to Financial Freedom blog, get with the times!
Why Was Marsman Stifled?
- Thread starter vanzandt
- Start date
Dude, you are 3 months late to the party. This thread has transformed to a Marsman's Journey to Financial Freedom blog, get with the times!
How do you know about marsman? You just became a member?
I don't see why you are finding issues with your assumption that he does not understand his trades.
Also, you could just be making an assumption that is false.
What is important is that he can build up his account, and that the drawdown are udner control.
My issue is that he doesn't want to do any serious risk management, while asking outsiders for money...
He doesn't get the risk involved, as I pointed out to him. And if you don't get what the risk is, you don't understand the trade... especially with options.
His draw-downs are not under control... because he uses full leverage to write strangles on high vol/low liquidity stocks, which means eventually he wil lose something like 10x premium or more. Which is exactly what happened the last time.
I'm not making assumptions, these are facts.
One thing that Magna did not mention is people like Marsman and Surf are not sponsors yet they want to use the site as if they were. I think Baron would let Marsman back if they paid as much as they ran their mouths. Until they pay they are treated as guests which means they have to behave and what they can say and do is limited. If they paid the rent I bet they would be able to run their mouths.
As I already explained it to you Mr. I Am On My 25th Handle, we don't give a shit about that anymore. We just want to know how the story ends. So keep up or get lost.
Now going back to topic, I think his backer probably asked him not to publicize the results not to mention tone the political outbursts down, so that's why we are not seeing new tweets...
Finally some words from him:
"Awaiting any moment a "decision day" in OPHT. IV is very high (300%). System is designed for it. SpotRange about +/- 90%."
I looked up OPHT on Seekingalpha:
Summary
Fovista, a new class of drugs, to treat Wet AMD.
Phase 2b Results showed Fovista + Lucentis to be statistically significant.
Phase 3 Results due out by the end of December 2016.
"Awaiting any moment a "decision day" in OPHT. IV is very high (300%). System is designed for it. SpotRange about +/- 90%."
I looked up OPHT on Seekingalpha:
Summary
Fovista, a new class of drugs, to treat Wet AMD.
Phase 2b Results showed Fovista + Lucentis to be statistically significant.
Phase 3 Results due out by the end of December 2016.
2 Possible Scenarios For Opthotech
Kyle Dennis, co-founder of biotechbreakouts.com, recently joined PreMarket Prep to share his thoughts on Opthotech Corp (NASDAQ: OPHT). According to Dennis, Opthotech will either be a huge hit or miss for traders within the next month.
The Answer Will Come Soon
Dennis pointed out that Opthotech shares have been driven down from above $60 to around $32 following disappointing data from competitor Regeneron Pharmaceuticals Inc (NASDAQ: REGN).
“Regeneron has some negative data with a drug that’s similar to what OPHT has,” Dennis explained.
“Traders and investors are speculating that OPHT is going to have bad data, but I don’t necessarily know that’s the case. I tend to be more positive on the name.”
Opthotech’s data is due out in December, and Dennis believes Opthotech stock will be on the move one way or another.
“It’s either going to be, in my opinion, a $15 stock or it’s going to be close to $100. It’s really important glaucoma data. If it is positive, it’s going to be transformative for this company,” he said.
He concluded the discussion by warning traders to expect extreme volatility in the stock following the release of the data. However, for traders that can stomach the risk, Opthotech is positioned for some major near-term upside.
At last check, Opthotech was trading down 9.46 percent at $30.81.
Kyle Dennis, co-founder of biotechbreakouts.com, recently joined PreMarket Prep to share his thoughts on Opthotech Corp (NASDAQ: OPHT). According to Dennis, Opthotech will either be a huge hit or miss for traders within the next month.
The Answer Will Come Soon
Dennis pointed out that Opthotech shares have been driven down from above $60 to around $32 following disappointing data from competitor Regeneron Pharmaceuticals Inc (NASDAQ: REGN).
“Regeneron has some negative data with a drug that’s similar to what OPHT has,” Dennis explained.
“Traders and investors are speculating that OPHT is going to have bad data, but I don’t necessarily know that’s the case. I tend to be more positive on the name.”
Opthotech’s data is due out in December, and Dennis believes Opthotech stock will be on the move one way or another.
“It’s either going to be, in my opinion, a $15 stock or it’s going to be close to $100. It’s really important glaucoma data. If it is positive, it’s going to be transformative for this company,” he said.
He concluded the discussion by warning traders to expect extreme volatility in the stock following the release of the data. However, for traders that can stomach the risk, Opthotech is positioned for some major near-term upside.
At last check, Opthotech was trading down 9.46 percent at $30.81.